# Rituximab

## Mabthera inj 100mg/10mL

##### 臨採

| TAH Drug Code      | [IMAB1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IMAB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Non-Hodgkin's Lymphoma - Indicated for the treatment of relapsed or chemotherapy-resistant low-grade B-cell non-Hodgkin's lymphoma in adult patients. - In combination with CVP chemotherapy, used for untreated indolent (follicular) B-cell non-Hodgkin's lymphoma in adult patients. - In combination with CHOP or other chemotherapy, used for CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in adult patients. - Used as maintenance therapy following a response to induction therapy in adult patients with follicular lymphoma. - In combination with chemotherapy, used for previously untreated advanced CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt leukemia (mature B-cell acute leukemia, BAL), or Burkitt-like lymphoma (BLL) in pediatric patients aged 6 months to under 18 years. Rheumatoid Arthritis - In combination with methotrexate, indicated for the treatment of adult patients with active rheumatoid arthritis who have not responded to one or more tumor necrosis factor (TNF) inhibitors or are intolerant to them. - In combination with methotrexate, indicated to slow the progression of joint damage as confirmed by X-ray in adult patients. Chronic Lymphocytic Leukemia - In combination with fludarabine and cyclophosphamide, indicated as a first-line treatment for CD20-positive chronic lymphocytic leukemia (CLL) in adult patients. - In combination with chemotherapy, indicated for the treatment of relapsed/refractory CD20-positive chronic lymphocytic leukemia. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - In combination with glucocorticoids, indicated for the treatment of pediatric (aged 2 years and older) and adult patients with granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) and microscopic polyangiitis (MPA). Pemphigus Vulgaris (PV) - In combination with glucocorticoids, indicated for the treatment of moderate to severe pemphigus vulgaris in adult patients. |
| Dosing             | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion, start at 100 mg/hour; if there is no infusion-related reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation), but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation. Active hepatits B disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting. Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% ) Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rituximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## MABTHERA infusion 500mg/50mL

##### 臨採

| TAH Drug Code      | [IMAB5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IMAB5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Non-Hodgkin's Lymphoma - Indicated for the treatment of relapsed or chemotherapy-resistant low-grade B-cell non-Hodgkin's lymphoma in adult patients. - In combination with CVP chemotherapy, used for untreated indolent (follicular) B-cell non-Hodgkin's lymphoma in adult patients. - In combination with CHOP or other chemotherapy, used for CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in adult patients. - Used as maintenance therapy following a response to induction therapy in adult patients with follicular lymphoma. - In combination with chemotherapy, used for previously untreated advanced CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt leukemia (mature B-cell acute leukemia, BAL), or Burkitt-like lymphoma (BLL) in pediatric patients aged 6 months to under 18 years. Rheumatoid Arthritis - In combination with methotrexate, indicated for the treatment of adult patients with active rheumatoid arthritis who have not responded to one or more tumor necrosis factor (TNF) inhibitors or are intolerant to them. - In combination with methotrexate, indicated to slow the progression of joint damage as confirmed by X-ray in adult patients. Chronic Lymphocytic Leukemia - In combination with fludarabine and cyclophosphamide, indicated as a first-line treatment for CD20-positive chronic lymphocytic leukemia (CLL) in adult patients. - In combination with chemotherapy, indicated for the treatment of relapsed/refractory CD20-positive chronic lymphocytic leukemia. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - In combination with glucocorticoids, indicated for the treatment of pediatric (aged 2 years and older) and adult patients with granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) and microscopic polyangiitis (MPA). Pemphigus Vulgaris (PV) - In combination with glucocorticoids, indicated for the treatment of moderate to severe pemphigus vulgaris in adult patients. |
| Dosing             | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion, start at 100 mg/hour; if there is no infusion-related reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation), but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation. Active hepatits B disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting. Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% ) Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rituximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

